We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+23.21%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$99.5M
AUM Growth
+$4.62M
(+4.9%)
Cap. Flow
-$4.26M
Cap. Flow
% of AUM
-4.28%
Top 10 Holdings %
Top 10 Hldgs %
44.59%
Holding
87
New
5
Increased
10
Reduced
44
Closed
4
Avg Time Held
5.6
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
2.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$996K |
| 2 |
NeuroOne Medical Technologies
NMTC
|
+$923K |
| 3 |
Ondas Inc
ONDS
|
+$831K |
| 4 |
Perion Network
PERI
|
+$700K |
| 5 |
MDxHealth
MDXH
|
+$447K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cantaloupe
CTLP
|
+$1.85M |
| 2 |
Exagen
XGN
|
+$1.16M |
| 3 |
Village Farms International
VFF
|
+$798K |
| 4 |
Natera
NTRA
|
+$635K |
| 5 |
Fastenal
FAST
|
+$394K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.43% |
| 2 | Technology | 23.96% |
| 3 | Communication Services | 10.24% |
| 4 | Industrials | 4.64% |
| 5 | Consumer Staples | 2.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$56.9B
| $7.73M | 7.77% |
45,750
-4,075
| -8% | -$635K |
2018 Q2
28 quarters
|
|
2
Eli Lilly
LLY
$1.08T
| $7.42M | 7.46% |
9,520
-275
| -3% | -$214K |
2013 Q2
48 quarters
|
|
3
Microsoft
MSFT
$3.96T
| $6.11M | 6.14% |
12,285
-100
| -0.8% | -$43.4K |
2014 Q1
45 quarters
|
|
4
Idexx Laboratories
IDXX
$41.7B
| $5.2M | 5.23% |
9,700
| – | – |
2013 Q3
47 quarters
|
|
5
Magnite
MGNI
$3.42B
| $3.26M | 3.28% |
135,125
-10,000
| -7% | -$147K |
2018 Q2
28 quarters
|
|
6
Inuvo
INUV
$7.77M
| $3.2M | 3.22% |
695,315
-6,217
| -0.9% | -$24.3K |
2018 Q2
28 quarters
|
|
|
7
MDxHealth
MDXH
$60.3M
| $3.14M | 3.16% |
1,420,025
+238,550
| +20% | +$447K |
2021 Q4
14 quarters
|
|
8
Abbott
ABT
$178B
| $2.96M | 2.97% |
21,743
-587
| -3% | -$77.4K |
2014 Q1
45 quarters
|
|
9
Advanced Micro Devices
AMD
$932B
| $2.74M | 2.75% |
19,304
-1,500
| -7% | -$163K |
2018 Q1
29 quarters
|
|
10
Axogen
AXGN
$2.06B
| $2.59M | 2.6% |
238,734
-14,800
| -6% | -$194K |
2013 Q3
47 quarters
|
|
11
LeMaitre Vascular
LMAT
$1.89B
| $2.55M | 2.56% |
30,711
-1,675
| -5% | -$140K |
2022 Q3
11 quarters
|
|
12
BlackSky Technology
BKSY
$722M
| $2.5M | 2.51% |
121,500
| – | – |
2024 Q3
3 quarters
|
|
13
Ooma
OOMA
$549M
| $2.46M | 2.47% |
190,804
-375
| -0.2% | -$4.77K |
2018 Q2
28 quarters
|
|
14
Digital Turbine
APPS
$1.16B
| $2.32M | 2.33% |
392,600
+5,000
| +1% | +$20.6K |
2023 Q4
6 quarters
|
|
15
Elutia
ELUT
$32.6M
| $2.28M | 2.3% |
1,153,977
+17,600
| +2% | +$35.6K |
2020 Q4
18 quarters
|
|
16
Veracyte
VCYT
$3.5B
| $2.22M | 2.23% |
81,950
-4,600
| -5% | -$133K |
2018 Q1
29 quarters
|
|
17
TELA Bio
TELA
$49.4M
| $1.7M | 1.71% |
875,865
-34,750
| -4% | -$45.5K |
2022 Q3
11 quarters
|
|
18
Personalis
PSNL
$1.7B
| $1.66M | 1.67% |
252,500
-4,807
| -2% | -$22.3K |
2024 Q2
4 quarters
|
|
|
19
Exagen
XGN
$204M
| $1.62M | 1.63% |
231,858
-191,113
| -45% | -$1.16M |
2019 Q3
23 quarters
|
|
20
Backblaze
BLZE
$602M
| $1.57M | 1.58% |
285,525
| – | – |
2022 Q3
11 quarters
|
|
21
Usio Inc
USIO
$78.6M
| $1.52M | 1.53% |
991,693
-4,000
| -0.4% | -$5.85K |
2022 Q4
10 quarters
|
|
|
22
Ondas Inc
ONDS
$3.58B
| $1.43M | 1.44% |
+744,005
| New | +$831K |
2025 Q2
0 quarters
|
|
|
23
Perion Network
PERI
$347M
| $1.31M | 1.31% |
128,675
+73,225
| +132% | +$700K |
2021 Q1
17 quarters
|
|
24
CryoPort
CYRX
$843M
| $1.27M | 1.28% |
170,050
+10,750
| +7% | +$66.7K |
2016 Q1
37 quarters
|
|
25
QuickLogic
QUIK
$174M
| $1.25M | 1.26% |
202,956
| – | – |
2019 Q2
24 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Perkins Capital Management held 87 positions worth $99.5M, up 4.9% from $94.8M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Perkins Capital Management withdrew a net $4.26M in Q2 2025, closing 4 positions and reducing 44 holdings. Its most notable exit was Cantaloupe, an estimated $1.85M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 62% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Inogen worth $1.04M.
- Perkins Capital Management's largest Q2 2025 buy was Inogen: 148,050 shares worth $1.04M.
- Perkins Capital Management added most to Perion Network in Q2 2025, an estimated $700K increase.
- Perkins Capital Management's biggest Q2 2025 reduction was Exagen, cutting an estimated $1.16M.
- Perkins Capital Management fully exited Cantaloupe in Q2 2025, selling an estimated $1.85M.
- Perkins Capital Management's ten largest holdings make up 45% of its $99.5M portfolio in Q2 2025.
- Perkins Capital Management opened 5 new positions and closed 4 in Q2 2025.
- Perkins Capital Management's portfolio value rose 4.9% quarter-over-quarter to $99.5M.
Based on Perkins Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.